Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 413946, 10 pages
http://dx.doi.org/10.1155/2014/413946
Research Article

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma

1School of Medicine and Pharmacology, University of Western Australia, M503, 23 Stirling Highway, Crawley, Perth, WA 6009, Australia
2National Centre for Asbestos Related Diseases, University of Western Australia, Nedlands, WA 6009, Australia
3PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, WA 6009, Australia
4Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
5School of Population Health, University of Western Australia, Crawley, WA 6009, Australia
6Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

Received 22 August 2014; Accepted 30 October 2014; Published 23 November 2014

Academic Editor: Jeffrey C. Gildersleeve

Copyright © 2014 Jenette Creaney et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Addis and H. Roche, “Problems in mesothelioma diagnosis,” Histopathology, vol. 54, no. 1, pp. 55–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. P. Chahinian, T. F. Pajak, J. F. Holland, L. Norton, R. M. Ambinder, and E. M. Mandel, “Diffuse malignant mesothelioma. Prospective evaluation of 69 patients,” Annals of Internal Medicine, vol. 96, no. 6, pp. 746–755, 1982. View at Publisher · View at Google Scholar · View at Scopus
  3. A. N. Husain, T. V. Colby, N. G. Ordonez et al., “Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 8, pp. 1317–1331, 2009. View at Google Scholar · View at Scopus
  4. N. G. Ordóñez, “What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update,” Human Pathology, vol. 38, no. 1, pp. 1–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. A. A. Renshaw, B. R. Dean, K. H. Antman, D. J. Sugarbaker, and E. S. Cibas, “The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma,” Chest, vol. 111, no. 1, pp. 106–109, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Stahel, W. Weder, and E. Felip, “Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 19, supplement 2, pp. ii43–ii44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Whitaker, “The cytology of malignant mesothelioma,” Cytopathology, vol. 11, no. 3, pp. 139–151, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. K. D. Wolanski, D. Whitaker, K. B. Shilkin, and D. W. Henderson, “The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses,” Cancer, vol. 82, no. 3, pp. 583–590, 1998. View at Publisher · View at Google Scholar
  9. A. Segal, G. F. Sterrett, F. A. Frost et al., “A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit,” Pathology, vol. 45, no. 1, pp. 44–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. H. E. Davies, R. S. Sadler, S. Bielsa et al., “Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 5, pp. 437–444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. I. Pass, A. Wali, N. Tang et al., “Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions,” Annals of Thoracic Surgery, vol. 85, no. 1, pp. 265–272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Creaney, D. Yeoman, L. K. Naumoff et al., “Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma,” Thorax, vol. 62, no. 7, pp. 569–576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Scherpereel, B. Grigoriu, M. Conti et al., “Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma,” The American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 10, pp. 1155–1160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Grigoriu, B. Chahine, F. Zerimech et al., “Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma,” Clinical Biochemistry, vol. 42, no. 10-11, pp. 1046–1050, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Alemán, J. M. Porcel, R. M. Segura et al., “Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions,” Medicina Clinica, vol. 133, no. 12, pp. 449–453, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Yamada, C. Tabata, R. Tabata, K. Fukuoka, and T. Nakano, “Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 10, pp. 1721–1726, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. College of American Pathologists Committee on Nomenclature and Classification of Disease, Systematized Nomenclature of Pathology, College of American Pathologists, Chicago, Ill, USA, 1965.
  18. R. W. Light, M. I. Macgregor, P. C. Luchsinger, and W. C. Ball Jr., “Pleural effusions: the diagnostic separation of transudates and exudates,” Annals of Internal Medicine, vol. 77, no. 4, pp. 507–513, 1972. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Threlfall, J. Thompson, and N. Olsen, Cancer in Western Australia: Incidence and Mortality 2003 and Mesothelioma 1960–2003, Western Australia Perth Statistical Series no. 74, Department of Health, 2005.
  20. A. Tung, S. Bilaceroglu, J. Porcel, J. Creaney, and Y. Lee, “Biomarkers in pleural diseases,” US Respiratory Disease, vol. 7, pp. 26–34, 2011. View at Google Scholar
  21. N. Boudville, R. Paul, B. W. S. Robinson, and J. Creaney, “Mesothelin and kidney function—analysis of relationship and implications for mesothelioma screening,” Lung Cancer, vol. 73, no. 3, pp. 320–324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Hollevoet, D. Bernard, F. de Geeter et al., “Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum,” Clinical Chemistry, vol. 55, no. 7, pp. 1431–1433, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Creaney, N. J. Olsen, F. Brims et al., “Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 9, pp. 2238–2246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Leigh and T. Driscoll, “Malignant mesothelioma in Australia, 1945–2002,” International Journal of Occupational and Environmental Health, vol. 9, no. 3, pp. 206–217, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. A. W. Musk and N. H. de Klerk, “Epidemiology of malignant mesothelioma in Australia,” Lung Cancer, vol. 45, supplement 1, pp. S21–S23, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. R. W. Light, “Tumor markers in undiagnosed pleural effusions,” Chest, vol. 126, no. 6, pp. 1721–1722, 2004. View at Publisher · View at Google Scholar · View at Scopus